Ransomware Tracker by ExposureDrift
Dashboard / Victims / PharmaEssentia Corporation

PharmaEssentia Corporation was listed on 09 September 2026 by the thegentlemen ransomware group (the group's claim; Ransomware Tracker by ExposureDrift has not confirmed a breach). thegentlemen listed 105 organizations that month and 1119 in total.

  • Listed 71 days ago.
  • 874 organizations were listed by all groups in September 2026, see the month.
  • 95 in Healthcare that month.
  • 7 in TW that month.

Updated 2026-11-19 05:35 UTC. Data: public leak-site listings. How we work.

PharmaEssentia Corporation corporate emblem
Listed by thegentlemen Disclosed: 2026-09-09 22:09 UTC

PharmaEssentia Corporation

pharmaessentia.com Healthcare TW

Threat Group Post & Evidence

Listed by
Thegentlemen 1,119 listings in total

The listing states no data size and no ransom demand.

No capture of the original post

We only show a screenshot when we captured the group's own page ourselves. For this listing we have not, so none is shown.

What the group says it holds

Taken from the group's own post. Ransomware Tracker by ExposureDrift has not seen the data and cannot confirm any of this.

pharmaessentia.com zoominfo.com/c/pharmaessentia-corp/145441146 PharmaEssentia Taiwanese global biopharma founded in 2003, known for besremi® (ropeginterferon alfa-2b) — the first drug developed in Taiwan ever approved by the FDA (2021) and the only polycythemia vera (PV) therapy approved in both the US and EU. Its innovation: a mono-pegylated long-acting interferon dosed every 2 weeks at home, with disease-modifying potential (reducing JAK2V617F mutant allele frequency) — a premium rare-disease asset vs. hydroxyurea and Jakafi. Financials: $197M+ revenue in 2024 (~89% gross margin), TPEX-listed (6446) with a ~5x stock rally since 2024; next bets: essential thrombocythemia (ET) Phase 3 and myelofibrosis. Bottom line: the Taiwanese biotech that proved a local startup can take a molecule from out-license to FDA approval and global commercialization — a rare-disease champion with an expandi…
Show the full post (908 characters)

pharmaessentia.com zoominfo.com/c/pharmaessentia-corp/145441146 PharmaEssentia Taiwanese global biopharma founded in 2003, known for besremi® (ropeginterferon alfa-2b) — the first drug developed in Taiwan ever approved by the FDA (2021) and the only polycythemia vera (PV) therapy approved in both the US and EU. Its innovation: a mono-pegylated long-acting interferon dosed every 2 weeks at home, with disease-modifying potential (reducing JAK2V617F mutant allele frequency) — a premium rare-disease asset vs. hydroxyurea and Jakafi. Financials: $197M+ revenue in 2024 (~89% gross margin), TPEX-listed (6446) with a ~5x stock rally since 2024; next bets: essential thrombocythemia (ET) Phase 3 and myelofibrosis. Bottom line: the Taiwanese biotech that proved a local startup can take a molecule from out-license to FDA approval and global commercialization — a rare-disease champion with an expanding moat.

Plain-English summary AI-written

The group says the post does not specify any data or files it holds.

Written by an AI model (openai/gpt-6-luna) from the post above. It can contain mistakes: rely on the quote, not the summary.

What to do about this listing

Choose who you are. Each step shows why it appears and, where we have one, its source. General guidance, not legal or incident-response advice.

If you work with PharmaEssentia (customer, supplier or partner)

Within 3 days

  • Do not open the group's page or download the data Do not visit the leak site or download files from a listing. Holding stolen data can be unlawful, and the files can carry malware. Wait for the company's own notice. Why: A safety rule for any leak listing.
  • Ask PharmaEssentia directly Write to your contact and ask whether your data, or your access to their systems, is in scope, and ask for a written statement. Your contract or data-protection law may oblige them to tell you if your data is affected: check the notification clause. Why: A listing is only the group's claim; the company is the one who can confirm what was taken.
  • Review what PharmaEssentia can reach of yours List the accounts, API keys, VPN or SSO connections and shared mailboxes this company has with you. Rotate the keys you gave them and remove access they do not need. Why: Access a supplier holds is how a listing about them can become a problem for you.

Within 30 days

  • Keep watching PharmaEssentia A supplier's listing can change after the first sighting: the group can add data, change the status or publish. Add the company to your supplier list to be told, and check your own domain too. Why: A listing is a moving claim, not a single event. Add to your supplier list Check your own domain
If you are PharmaEssentia

Within 3 days

  • Find out what was actually taken The post names no specific kind of data, so no data-specific steps are shown. Check the group's own post and your logs to learn what is claimed and what is real. Why: The listing text names no data types.
  • Remove dangling DNS records Delete or re-point records that allow subdomain takeover. Why: A passive scan found 2 dangling subdomain(s).
  • Retire staging and dev exposure Take non-production hosts off the internet or behind authentication, and rotate any secrets they held. Why: A passive scan found 1 non-production host(s) that are public.
  • Check regulatory and stakeholder notification duties Health data adds sector rules. This is general guidance, not legal advice: confirm current rules with counsel. Why: The listing or sector points to health data.

Within 30 days

  • Check shared suppliers and software List the suppliers and software you share with other Healthcare organizations and ask them whether they were affected. Why: thegentlemen listed 59 other Healthcare organization(s) in the last 90 days.
General readiness for any ransomware claim (not about this listing)
  • Offline, immutable backups and a restore drill Keep backups outside domain-admin reach and practise a restore; a leak does not remove the risk of re-encryption. Why: General practice for any ransomware claim; not specific to this listing.
  • Look for mass file access and unusual outbound transfers Review EDR, proxy and identity logs for bulk reads, archive creation and large uploads to file-sharing services. Why: General practice for any ransomware claim; not specific to this listing.
  • Phishing-resistant MFA on remote access Enforce MFA on VPN, SSO and admin panels, and retire password-only or SMS-based remote access. Why: General practice for any ransomware claim; not specific to this listing.

Listing details

Resolved Domain pharmaessentia.com
Industry Vertical Healthcare
Country TW
Enrichment Status ENRICHED

Listing severity score (heuristic)

91/100 • CRITICAL

A heuristic built from sector, group, data volume and claim details. It is not evidence that a breach occurred or a measure of harm.

1. Sector Criticality 30/30 pts
Healthcare and life sciences
2. Group tier 25/25 pts
Tier 1: among the groups with the most listings in our data
3. Data Volume & PII Scope 18/25 pts
Larger claim: gigabytes, or business or financial records named in the post
Formula: sector • group tier • data claimed (scaled to 100) Rule-based score

External Attack Surface Profile

ASM Intelligence
96/100 • CRITICAL
Last Audited: 2026-11-14 16:10 UTC Passive Recon
Total Network Assets 15
3 hosts • 12 unique IPs
2 cloud-hosted • 5 SaaS
Subdomain Assets 3
Critical Panels 0 (VPN/Admin/SSO)
Non-Prod / UAT 1 Staging/Dev
SaaS Ecosystem 5 Cloud Apps
Primary CSP Amazon Web Servi
Email Security Grade A (SPF/DMARC)
Open the full attack surface scan →
Is Your Organization Exposed?

Run a free passive scan on your own domain to see what an attacker can see from the outside.

Defense Telemetry

Passive DNS
Mail Gateway Mimecast Secure Gateway
DNS Authority Authoritative DNS (tw)
Edge CDN / Shield None
SPF Record Configured
DMARC Policy Enforced
Public DNS records only • no port scanning

More Claims by thegentlemen

All →
AARP
Healthcare 2026-11-18 09:22 UTC
NVIDIA
Technology 2026-11-18 09:22 UTC
BAE Exchange
Financial Services 2026-11-17 16:56 UTC
Rosenberger Legal
Professional Services 2026-11-17 16:56 UTC
Bio architecture Formosana
Agriculture and Food Production 2026-11-17 16:56 UTC
Ebema
Manufacturing 2026-11-17 16:55 UTC